Dendrite Acquires Assets of OPUS Health, a Leading Supplier of Patient Persistence Technology

Dendrite International, Inc. (NASDAQ:DRTE) a leading
provider of sales and marketing solutions to the pharmaceutical
industry, today announced the acquisition of substantially all the
assets of OPUS Health LLC, a leading provider of direct-to-patient
persistence technologies. The acquisition cements an existing
agreement between the two companies that enables Dendrite to provide
the industry's most complete end-to-end, multi-channel persistence
solution, which links pharmaceutical companies, prescribers,
pharmacies and patients. OPUS Health will operate as a division of
Dendrite within the Marketing Solutions business.
   Patient persistence is a far-reaching problem for all key
healthcare constituents: patient, provider, payor,
pharmaceutical/biotech manufacturer, pharmacy and government. Simply
put, when patients don't take their medications properly, it lessens
the health benefit for the patient and thereby increases costs for the
entire system. Dendrite believes patient persistence programs will be
a large market and ultimately evolve into an even larger disease
management market.
   OPUS Health is an early-stage company and pioneer in
direct-to-patient technologies. Dendrite adds its breadth of marketing
services around OPUS Health technology to deliver complete patient
persistence programs and analysis. As partners, Dendrite and OPUS
Health have already provided such programs for more than 40
pharmaceutical brands. This strategic acquisition allows Dendrite to
reinforce its early lead in the first generation of electronic
direct-to-patient programs and position it for leadership in future
generations of these technologies.
   "The acquisition of OPUS Health is consistent with our strategy to
be a leader in direct-to-patient persistence solutions," said Carl
Cohen, president of Dendrite Marketing Solutions. "Patients respond to
the solution because of its ease of use, instant point-of-sale nature,
and availability at their local pharmacies. Our customers and other
healthcare constituents value the end-to-end nature of our programs,
which improve patient health and help lower overall costs."
   "Dendrite has always been an industry visionary and we are glad to
be joining the Dendrite family," said Harvey Brofman, vice president
and general manager of the OPUS Health group at Dendrite. "With the
acquisition of OPUS Health into its Marketing Solutions group,
Dendrite has a more powerful, streamlined solution in the area of
patient persistence. We also believe that being part of Dendrite can
enhance our product offering to partners and strengthen our
relationships with them."

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com. For
more information on OPUS Health, please visit www.opushealth.com.

   About OPUS Health

   OPUS Health assets were sold to Dendrite by OCI Ventures, LLC a
privately held company whose other Division, OPUS-ISM, LLC is a
leading provider of pharmacy management systems and pharmacy workflow
technology to retail pharmacies, HMOs and PBMs.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers, including the risk associated
with one substantial customer currently assessing its U.S. sales force
effectiveness services needs; our ability to successfully implement
our Operational Effectiveness program and to achieve the cost savings
in the amounts and time periods expected or budgeted; changes in
demand for our products and services attributable to any weakness
experienced in the economy or mergers, acquisitions and consolidations
in the pharmaceutical industry; risks associated with foreign currency
fluctuations and our ability to adapt and respond successfully to
other unique risks involved in our non-U.S. operations; integrating
the entities we acquire; and our ability to effectively manage our
growth. Other important factors that should be reviewed and carefully
considered are included in the company's 10-K, 10-Qs, and other
reports filed with the SEC. Actual results may differ materially. The
company assumes no obligation for updating any such forward-looking
statements to reflect actual results, changes in assumptions or other
changes affecting such forward-looking statements and the information
provided in this press release should not be construed as updating,
modifying or confirming the company's most recent financial outlook or
guidance.